Tessera Therapeutics’ $230 million Series B Financing Round

Goodwin Procter LLP advised Tessera Therapeutics on the deal.

Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised over $230M in Series B financing. The round was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2i, with participation from Qatar Investment Authority (QIA) and others.

Tessera will use the latest round of funding to accelerate research and development in the company’s Gene Writing technologies, expand its team, and establish manufacturing and automation capabilities critical for its platform and programs. This investment will accelerate the company’s ability to position multiple therapeutic programs for clinical development.

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source.

Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability.

The Goodwin team was led by Stuart Cable (Picture), Arthur McGivern, Patricia Mets, Qing Han, Wenlan Geng and Alexandra Haas.

Involved fees earner: Stuart Cable – Goodwin Procter; Wenlan Geng – Goodwin Procter; Qing Han – Goodwin Procter; Arthur McGivern – Goodwin Procter; Patricia Mets – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Tessera Therapeutics;

Author: Martina Bellini